Amsterdam, The Netherlands and Irvine, CA – Agendia, Inc. announced at the American Association for Cancer Research Annual Meeting 2016 (New Orleans, LA) that using the company’s MammaPrint® assay, patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria can avoid chemotherapy. The MammaPrint® assay is the first and only genomic test to receive level 1A clinical utility evidence for chemotherapy benefit in early breast cancer patients.

Gilde Healthcare acted as founding investor of Agendia when it was spun off from the Netherlands Cancer Institute/Anthonie van Leeuwenhoek hospital in 2004. Gilde actively supported the growth of Agendia from its research stage to a global molecular diagnostics company.

Full press release: http://www.agendia.com/agendias-mammaprint-first-and-only-genomic-assay-to-receive-level-1a-clinical-utility-evidence-for-chemotherapy-benefit-in-early-breast-cancer-patients/

About Gilde Healthcare

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, MA) is a transatlantic growth capital firm focused on private healthcare technology and service companies. It has over €800 million under management and is actively looking to lead new investments in digital health, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €30 million in a single portfolio company. For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

About Agendia

Agendia (Amsterdam, The Netherlands and Irvine, CA) is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. The lead products include the FDA-cleared MammaPrint® FFPE as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint®, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods. For more information, visit www.agendia.com.